Bringing the fundamentals into focus…
Bringing the fundamentals into focus…
ANRO · against 1,336 other Healthcare companies
Ranked #953 of 1,337 · scores higher than 8% of peers
Bars: peers in each 10-point band of the valuation score385 peers with a valuation score of 0–9, including ANRO · Click a bar to see the companies
Mainly because of its EBITDA yield, earnings yield and free cash flow yield, which are weaker than most Healthcare peers.
| Metric | ANRO | Peer median | Better than | Position among peers | Weight |
|---|---|---|---|---|---|
| Earnings yieldHigher is better · 1,287 reported | -9.8% | 1.5% | 20% | 30% | |
| EBITDA yieldHigher is better · 1,357 reported | -13.1% | 4.2% | 14% | 50% | |
| Free cash flow yieldHigher is better · 711 reported | -7.7% | -1.0% | 31% | 20% | |
| Book yieldHigher is better · 1,306 reported | 27.5% | 37.9% | 38% | Context only |
| Rank | Company | Market cap | Valuation | Overall |
|---|---|---|---|---|
| 1 | 21.3B HKD (≈$2.7B) | 99 | 68 | |
| 1 | 1.1B HKD (≈$146M) | 99 | 72 | |
| 1 | 14.2B HKD (≈$1.8B) | 99 | 64 | |
| 1 | 52.2B HKD (≈$6.7B) | 99 | 56 | |
| 1 | 3.5B HKD (≈$451M) | 99 | 51 | |
| 953 | 841M USD | 8 | 33 | |
Scores are sector-relative percentiles from the latest snapshot, always calculated against the whole sector: narrowing the comparison group changes who you compare with, not the scores. Missing metrics are left out and the remaining weights rescaled. How we score
| 953 |
| 397M USD |
| 8 |
| 37 |
| 953 | 3.7B USD | 8 | 31 |
| 953 | 794M USD | 8 |
| 953 | 891M USD | 8 |
| 953 | 10.2B USD | 8 |
| 953 | 487M USD | 8 | 24 |
| 953 | 17M USD | 8 | 16 |
| 953 | 271M USD | 8 | 14 |